We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 2,737

NJ court affirms role of learned intermediary doctrine
  • Shook Hardy & Bacon LLP
  • USA
  • May 26 2015

A New Jersey court overseeing the centralized litigation regarding the human tissue product AlloDerm has issued a noteworthy ruling in a bellwether


Pharmaceutical marketing and unfair-trade-practices claims
  • Ellis & Winters
  • USA
  • May 26 2015

Lawsuits against pharmaceutical companies generally center on product-liability claims. A new trend in pharma cases, however, is to include a


Sixth Circuit holds that cases directly filed in MDLs are governed by law of where case would have been filed
  • Bradley Arant Boult Cummings LLP
  • USA
  • May 26 2015

On May 22, 2015, the United States Court of Appeals for the Sixth Circuit Court of Appeals addressed an important choice-of-law issue for parties


California federal court gets tough on off-label promotion FCA claims
  • Dechert LLP
  • USA
  • May 19 2015

Modglin v. DJO Global Inc., 2015 U.S. Dist. LEXIS 60812 (C.D. Cal. May 8, 2015) is one of those cases that has so much good stuff going on, we just


Amarin Pharma sues FDA over constitutional right to discuss off-label uses
  • Baker & Hostetler LLP
  • USA
  • May 14 2015

Drug makers and the Food and Drug Administration (FDA) have often disagreed over whether drug makers can discuss unapproved uses for their products


Law review articles that caught our eye
  • Reed Smith LLP
  • USA
  • May 14 2015

Maybe our motto here at DDLaw should be "we read law review articles so you don't have to." Here are a couple of recent ones that looked interesting


Drug manufacturer and doctors sue FDA regarding off-label use
  • Weil Gotshal & Manges LLP
  • USA
  • May 13 2015

Last week, a pharmaceutical company, Amarin Pharma, Inc. (“Amarin”), along with a group of physicians, filed a complaint against the U.S. Food and


医薬品の安全性に関するラベルジェネリック医薬品とブ ランド医薬品
  • Jenner & Block
  • USA
  • May 13 2015

FDAの規制によりジェネリック医薬品はブランド 医薬品と化学的に同等であり同じ有効成分を有し かつ生物学的に同等であることが求められるしか しブランド医薬品製造業者が製薬のラベルの正確性 につき責任を有する一方ジェネリック医薬品製造業


Drug safety labeling: generic versus branded
  • Jenner & Block
  • USA
  • May 13 2015

Under FDA regulations, generic drugs must be chemically equivalent, have the same active ingredients, and be bioequivalent to their branded


Time and preemption
  • Reed Smith LLP
  • USA
  • May 13 2015

The time for Mad Men is almost over. Next Sunday is the finale, and we can hardly stand the thought that our tv screens will no longer harbor Don